CathVision Makes History: First Patient Enrolled in Revolutionary Persistent AF Study at OLV Hospital Aalst

CathVision, a medical technology company developing state-of-the-art electrophysiology solutions to optimize clinical decision-making in the EP lab, is proud to announce the enrollment of the first patient in a groundbreaking follow-up clinical study at OLV Hospital Aalst in Belgium. Led by Dr. Tom De Potter, the study aims to showcase the remarkable value of the Signal Complexity™ algorithm and its potential to revolutionize the EP lab.

Atrial fibrillation is a growing health issue, with an estimated 46 million people worldwide currently suffering from the condition. With factors such as obesity, hypertension and physical inactivity on the rise, it is predicted that one in three individuals over the age of 40 will experience AF at some point.

Unfortunately, 75% of AF patients have persistent or permanent forms of the condition, resulting in only a 50% success rate in terms of freedom from AF at 12 months following therapy. Thankfully, technological advances are providing new opportunities to improve the effectiveness of treatments.

Dr. Tom De Potter, Associate Director of the Cardiovascular Center at OLV Hospital in Aalst, explains the difficulty of assessing the impact of an ablation procedure in real-time. When an ablation procedure starts and ends in AF rhythm, it is often hard to tell if the strategy is progressing positively, which affects the duration and outcome of the procedure. Integrating a reliable solution to affirm the ablation impact would provide immense value.

Dr. De Potter is set to put Signal Complexity, a revolutionary algorithm designed to measure and visualize rhythm parameters such as cycle length, variability, fractionation, and dominant frequency in real time, to the test. Signal Complexity utilizes high-fidelity, low-noise cardiac data obtained from the ECGenius System™ by CathVision to track the progress of ablation procedures during persistent atrial fibrillation (AF).

The algorithm promises to provide automated analyses that can help physicians improve clinical outcomes and efficiency. Dr. De Potter will evaluate the clinical utility of Signal Complexity to analyze the impact of ablation therapy in coordination with pulmonary vein isolation (PVI) plus individually mapped ablation targets.

CathVision’s CARDIALYTICS™ suite of powerful AI analytics, which includes Signal Complexity, PVI Analyzer™, and FaST Mapping, is undergoing clinical evaluation at NYU Langone Health. 28 patients have already been enrolled, and data gathered from the evaluation will be presented at the upcoming Heart Rhythm Society meeting in New Orleans. With Signal Complexity, CathVision is paving the way for an exciting new era of cardiac care.

“It is truly exciting to witness the mounting clinical evidence that speaks to the need for our ECGenius System and CARDIALYTICS suite, paving the way for a new age of EP recording systems,” enthused Mads Matthiesen, CEO of CathVision. “We remain steadfast in our commitment to delivering real value to clinicians.”

About CathVision

CathVision is revolutionizing the way physicians diagnose, characterize, and treat heart rhythm disorders. Through its innovative EP recording system and AI algorithm platform – the ECGenius System – CathVision is empowering physicians to make more informed decisions in the EP lab. Founded in 2013 and headquartered in Denmark with a U.S. office in Minnesota, CathVision is committed to reimagining the necessity of exceptional cardiac electrical signals for a more accurate diagnosis.

Leave a Comment